Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
about
Current status of biomarkers for prostate cancerActive surveillance and focal therapy for low-intermediate risk prostate cancerMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerHuman phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progressionBiologic differences between peripheral and transition zone prostate cancerAbiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsLow-grade prostate cancer diverges early from high grade and metastatic disease.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.Should Gleason 6 be labeled as cancer?Gleason grade progression is uncommon.A molecular signature predictive of indolent prostate cancer.Defining the threshold for significant versus insignificant prostate cancer.Prognostic prostate tissue biomarkers of potential clinical use.Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.Tumour heterogeneity: principles and practical consequences.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.Molecular correlates of intermediate- and high-risk localized prostate cancerThe Clinical Genomics of Prostate Cancer
P2860
Q24600574-A9B9CFB7-9325-499C-9487-CDA12BD898EEQ26773641-5908AF0D-4B11-4BFB-80E4-210DD2FD3594Q27024775-2753D4DE-5325-453E-8694-FB4F2D3DB76EQ28269917-18EED073-7FBD-4A10-AD1E-9241A3DB6090Q34734506-190166E2-DA07-4C03-B2FD-8DCD5B69DE20Q35178389-A6DEC6CC-E649-4D31-8B7A-C48CEA260C87Q35180364-0B333DE1-D19F-4564-9E80-F17FC2C69873Q35678391-18B1725B-1BFA-4F95-B5ED-18100014A516Q36259221-CFD71424-75BC-46E8-ACD1-BD87D10DBFDFQ36469889-C06167DD-0128-4CFF-99E8-F2E4164E0419Q36888450-37C64E37-7793-4179-B002-F2C95E90332DQ36931932-E5CE4B8C-36A7-446B-A8C9-22E2467070FFQ37177744-24D233B9-D546-4106-A95B-D1CC88B64CBAQ37618807-253EA3C6-AE86-4182-8B96-B12CA851EA1EQ38109810-BC53E158-A8F3-48EC-8E4B-5FD6D7E52422Q38184382-922A130A-74B5-49D1-9A36-D61C7005237EQ38356863-901F264D-1B47-4E7E-B7B8-E0BA5D7A3CB9Q38610286-038EE8C7-4FC4-41C8-AD41-728756F48652Q38764526-E185F1A5-C225-458B-8DBA-C2AD8C9C994CQ38842168-FEDFEC3B-DCB6-46E4-B968-DB51530D36D4Q39108592-8B8CF616-9527-4CDD-B1C1-401D514063ACQ40996353-5427A316-6500-411C-887F-CC1C809A9EABQ41912121-38849D6B-E46C-4043-A206-E2B2D6B4B6CBQ43089446-685A38EB-6267-4F00-932D-97797F2D2B36Q43269413-E176FB5A-22F6-4EC7-8F2A-59AA23FB8ABBQ45978540-8160AC1D-EC23-4C17-BF80-336C17D0EBEBQ51549809-376ADC47-26FF-4BFE-9C0C-98C29B67F0D5Q53569770-83EDC01E-825C-4B17-BB80-203809D99B82Q57109051-79642C6F-5E5A-4C92-8275-7744D10D7E3EQ57288339-682A542C-B3F4-4CFE-8076-220BEE8612A0
P2860
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@ast
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@en
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@nl
type
label
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@ast
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@en
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@nl
prefLabel
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@ast
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@en
Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
@nl
P2093
P2860
P1433
P1476
Clonal progression of prostate cancers from Gleason grade 3 to grade 4
@en
P2093
Glenn J Bubley
Steven P Balk
P2860
P304
P356
10.1158/0008-5472.CAN-12-2799
P407
P577
2012-11-30T00:00:00Z